Avalo Therapeutics AVTX
$6.76 +$0.01 (+0.15%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $6.76 0.00%
Open$6.65
Prev close$6.75
Day range$6.61 – $7.03
Volume1.18M
Market cap$390.88M
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$0.00
Operating profit-$23.40M-21.9% YoY
Net profit-$18.95M+38.1% YoY
Diluted EPS-$0.34+84.5% YoY
Free cash flow-$11.54M+29.5% YoY
Operating cash flow-$11.54M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Operating margin-161,962.7%
Net margin-150,259.3%
Return on equity-33.6%
Return on assets-29.2%
Return on invested capital-33.5%
Current ratio16.63
Liabilities / assets9.3%
Cash & investments$392.97M
Total debt$0.00
Net cash (debt)$392.97M
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Operating Revenue | $0.00 | $0.00 | $0.00 | $59,000.00 | $59,000.00 |
| Operating Expense | $23.40M | $31.52M | $20.90M | $72.98M | $19.80M |
| Selling and Admin Expenses | $8.35M | $8.10M | $6.85M | $22.90M | $6.53M |
| -Selling & Marketing Expense | $123,000.00 | $126,000.00 | $209,000.00 | $470,000.00 | $381,000.00 |
| -General & Admin Expense | $8.23M | $7.97M | $6.65M | $22.43M | $6.15M |
| Research & Development | $15.05M | $23.42M | $14.05M | $50.08M | $13.27M |
| Operating Profit | -$23.40M | -$31.52M | -$20.90M | -$72.93M | -$19.74M |
| Net Non-Operating Interest Income (Expense) | $4.25M | $2.76M | $803,000.00 | $4.35M | $992,000.00 |
| Non-Operating Interest Income | $4.25M | $2.76M | $803,000.00 | – | – |
| Other Income (Expense) | $210,000.00 | -$7.58M | $480,000.00 | -$9.52M | $5.16M |
| Gain on Sale of Security | $210,000.00 | -$1.01M | $480,000.00 | -$9.52M | $5.16M |
| Special Income (Charges) | $0.00 | -$6.57M | – | $0.00 | $0.00 |
| -Less:Restructuring and Mergern & Acquisition | $0.00 | $6.57M | – | $0.00 | $0.00 |
| Pretax Profit | -$18.94M | -$36.34M | -$19.62M | -$78.09M | -$13.59M |
| Tax | $7,000.00 | $18,000.00 | $12,000.00 | $165,000.00 | $130,000.00 |
| Net Profit | -$18.95M | -$36.36M | -$19.63M | -$78.26M | -$13.72M |
| Profit from Continuing Operations | -$18.95M | -$36.36M | -$19.63M | -$78.26M | -$13.72M |
| Net Income to Parent Company | -$18.95M | -$36.36M | -$19.63M | -$78.26M | -$13.72M |
| Net Income to Common Stockholders | -$18.95M | -$36.36M | -$19.63M | -$78.26M | -$13.72M |
| Basic EPS | -$0.34 | -$0.83 | -$0.98 | -$5.84 | -$0.37 |
| Diluted EPS | -$0.34 | -$0.83 | -$0.98 | -$5.84 | -$0.37 |
| Total Revenue as Reported | – | – | – | $59,000.00 | $59,000.00 |
| Cost of Revenue | – | – | – | $0.00 | $0.00 |
| Gross Profit | – | – | – | $59,000.00 | $59,000.00 |
| Total Other Finance Costs | – | – | – | -$4.35M | – |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $481.43M | $490.78M | $99.89M | $116.46M | $116.46M |
| Total Current Assets | $400.74M | $407.93M | $88.83M | $105.29M | $105.29M |
| Cash and Cash Equivalents & Short-Term Investments | $392.97M | $400.28M | $81.99M | $98.34M | $98.34M |
| -Cash and Cash Equivalents | $64.99M | $85.38M | $24.99M | $15.86M | $15.86M |
| -Short Term Investments | $327.98M | $314.89M | $57.01M | $82.48M | $82.48M |
| Restricted Cash | $211,000.00 | $49,000.00 | $147,000.00 | $37,000.00 | $37,000.00 |
| Other Current Assets | $7.56M | $7.61M | $6.69M | $6.91M | $6.91M |
| Total Non-Current Assets | $80.70M | $82.85M | $11.06M | $11.17M | $11.17M |
| Net PPE | $198,000.00 | $288,000.00 | $375,000.00 | $460,000.00 | $460,000.00 |
| Investments and Advances | $69.81M | $71.88M | – | – | – |
| Goodwill and Other Intangible Assets | $10.50M | $10.50M | $10.50M | $10.50M | $10.50M |
| -Goodwill | $10.50M | $10.50M | $10.50M | $10.50M | $10.50M |
| Other Non-Current Assets | $183,000.00 | $183,000.00 | $183,000.00 | $210,000.00 | $210,000.00 |
| Total Liabilities | $44.88M | $42.12M | $31.57M | $33.41M | $33.41M |
| Total Current Liabilities | $24.09M | $21.13M | $11.60M | $12.94M | $12.94M |
| Payables | $2.46M | $3.35M | $683,000.00 | $464,000.00 | $464,000.00 |
| -Accounts Payable | $2.46M | $3.35M | $356,000.00 | $137,000.00 | $137,000.00 |
| Current Accrued Expenses | $17.13M | $14.74M | $8.84M | $7.95M | $7.95M |
| Short-Term Debt and Capital Lease Obligation | $153,000.00 | $242,000.00 | $328,000.00 | $392,000.00 | $392,000.00 |
| -Current Capital Lease Obligation | $153,000.00 | $242,000.00 | $328,000.00 | $392,000.00 | $392,000.00 |
| Total Non-Current Liabilities | $20.79M | $20.99M | $19.97M | $20.47M | $20.47M |
| Long Term Debt and Capital Lease Obligation | $0.00 | $0.00 | $0.00 | – | – |
| -Long Term Capital Lease Obligation | $0.00 | $0.00 | $0.00 | – | – |
| Derivative Product Liabilities | $18.32M | $18.53M | $17.52M | $18.00M | $18.00M |
| Non-Current Deferred Liabilities | $470,000.00 | $463,000.00 | $446,000.00 | $434,000.00 | $434,000.00 |
| Convertible preferred securities | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Other Non-Current Liabilities | $2.00M | $2.00M | $2.00M | $2.04M | $2.04M |
| Total Equity | $436.55M | $448.66M | $68.32M | $83.05M | $83.05M |
| Stockholders' Equity | $436.55M | $448.66M | $68.32M | $83.05M | $83.05M |
| Capital Stock | $54,000.00 | $53,000.00 | $25,000.00 | $18,000.00 | $18,000.00 |
| -Common Stock | $54,000.00 | $53,000.00 | $25,000.00 | $18,000.00 | $18,000.00 |
| -Preferred Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Additional Paid-In Capital | $961.46M | $953.70M | $536.45M | $531.49M | $531.49M |
| Retained Earnings | -$523.46M | -$504.51M | -$468.15M | -$448.52M | -$448.52M |
| Gains/Losses Not Affecting Retained Earnings | -$1.51M | -$583,000.00 | -$6,000.00 | $68,000.00 | $68,000.00 |
| -Other Payable | – | – | $327,000.00 | $327,000.00 | $327,000.00 |
| -Gross PPE | – | – | – | $713,000.00 | $713,000.00 |
| -Accumulated Depreciation | – | – | – | -$253,000.00 | -$253,000.00 |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$11.54M | -$19.99M | -$17.69M | -$51.46M | -$14.25M |
| Net cash flow from continuing operations | -$11.54M | -$19.99M | -$17.69M | -$51.46M | -$14.25M |
| Net Income from Continuing Operations | -$18.95M | -$36.36M | -$19.63M | -$78.26M | -$13.72M |
| Gain/Loss from Continuing Operations | -$210,000.00 | $1.01M | -$480,000.00 | $9.52M | -$5.16M |
| Depreciation & Depletion & Amortization | $18,000.00 | $17,000.00 | $17,000.00 | $344,000.00 | $16,000.00 |
| Deferred Tax | $7,000.00 | $17,000.00 | $12,000.00 | $165,000.00 | $131,000.00 |
| Other Non-Cash Items | $0.00 | $1.87M | -$106,000.00 | -$690,000.00 | – |
| Change in Working Capital | $3.09M | $8.68M | -$1.08M | $3.84M | $176,000.00 |
| -Change in Prepaid Assets | $49,000.00 | -$922,000.00 | $228,000.00 | -$2.59M | -$4.77M |
| -Change in Payables and Accrued Expense | $3.05M | $9.62M | -$1.28M | $6.52M | $5.01M |
| -Change in Other Current Liabilities | -$17,000.00 | -$16,000.00 | -$31,000.00 | -$87,000.00 | -$63,000.00 |
| Net cash flow from investing | -$11.23M | -$329.93M | $25.51M | -$81.72M | $2.40M |
| Net Cash Flow from Continuing Investing Activities | -$11.23M | -$329.93M | $25.51M | -$81.72M | $2.40M |
| Net Investment Purchase and Sale | -$11.23M | -$329.93M | $25.51M | -$81.72M | $2.40M |
| Financing Cash Flow | $2.54M | $410.21M | $1.40M | $14.59M | $687,000.00 |
| Net Cash Flow from Continuing Financing Activities | $2.54M | $410.21M | $1.40M | $14.59M | $687,000.00 |
| Net Common Stock Issuance | $0.00 | – | – | $14.76M | $392,000.00 |
| Proceeds from Stock Option Exercised | $2.54M | $5.30M | $2.18M | $797,000.00 | $757,000.00 |
| Net Other Financing Charges | $0.00 | -$26.40M | -$779,000.00 | -$972,000.00 | -$462,000.00 |
| Ending Cash Balance | $65.38M | $85.61M | $25.32M | $16.11M | $16.11M |
| Net Change in Cash | -$20.23M | $60.30M | $9.21M | -$118.59M | -$11.16M |
| Beginning Cash Balance | $85.61M | $25.32M | $16.11M | $134.70M | $27.26M |
| Free Cash Flow | -$11.54M | -$19.99M | -$17.69M | -$51.46M | -$14.25M |
| -Change in Receivables | – | – | – | $0.00 | – |
| Net Business Purchase and Sale | – | – | – | $0.00 | $0.00 |
No comments yet — be the first to weigh in on AVTX.
Sign in to join the discussion.